Scleroderma and Lupus Health Study Claims No Environmental Link To Disease PDF Print E-mail
Friday, 08 January 2010 22:09
taken from http://www.flickr.com/photos/h_de_c/3291978657/ via creative commonsThe Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of scleroderma and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed statistically significantly higher than expected among Caucasian females. No specific associations with environmental exposures were identified.

The study did confirm that a previous diagnosis of rheumatoid arthritis was associated with scleroderma and lupus among current and former South Boston residents. Further, the study also found that a family history of specific rheumatic diseases was significantly associated with a diagnosis of scleroderma and lupus.

The Department of Public Health's study was initiated in 1998, as a result of concerns raised by the South Boston community and then-State Senator Stephen F. Lynch, who now represents Massachusetts' 9th congressional district. At that time, the community expressed concerns about a perceived increase in the number of women who had grown up in South Boston and were later diagnosed with scleroderma. Community members also expressed concern about possible environmental exposure.

"The release of this study represents more than ten years of collaboration between the Massachusetts Department of Public Health and the South Boston community to address concerns of the prevalence of scleroderma and lupus," Congressman Stephen F. Lynch said. "I am pleased to see that this study has been completed and the results will guide future research and help those living with these chronic diseases."

DPH Commissioner John Auerbach added, "These types of studies are important and enhance our collaboration with community partners to improve public health."

DPH responded to the communities’ concerns by collaborating with clinical researchers and epidemiologists at Boston Medical Center, Tufts Medical Center and the South Boston Community Health Center to conduct a retrospective case-control study to investigate the occurrences of both diseases and to identify possible contributing factors (environmental and non-environmental) among individuals with scleroderma and lupus. In addition, DPH established a South Boston Community Advisory Committee to facilitate community outreach and ongoing communication.

Study participants were interviewed about their residential, occupational, medical, family and reproductive histories, as well as hobbies and recreational activities in the area. The study also investigated possible historical exposures to a number of sources of environmental pollution, as well as spatial and temporal (time) patterns among current and former residents with these diseases.

Source: Office of Health and Human Services (EOHHS)

If you're logged in, you can download a copy of the report, presentation, and questions and answers below.

 
More articles :

» Moves Toward Personalized Medicine for Scleroderma

researchers have received two five-year grants totaling $953,000 from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases to study , an autoimmune disease for which there currently is no...

» Unite Against Scleroderma 2014

For the fourth year running, we will be hosting our annual “Unite Against Scleroderma” Awareness Walk. Scheduled to start from 2:30pm, the Walk would be held on Saturday 3rd May, 2014 and cover one full lap around the Queen’s Park Savannah,...

» Important Information On Flaxseed And Flaxseed Oil

Flaxseed, called linseed in some countries, is a good source of dietary fiber, , and . Each of these components may contribute to the health effects of eating flaxseed, but flaxseed oil contains no fiber and very little lignan. In addition to its...

» arGentis Continues To Expand

But arGentis grew its drug-development pipeline this month with the acquisition of the rights to a rheumatoid arthritis therapy from the - the terms of which, were not disclosed. The treatment was developed at the University of Tennessee Health...

» June Is Scleroderma Awareness Month!

The month of June is Scleroderma Awareness Month around the world, and would like to encourage each and everyone of you, to become advocates by raising awareness and educating others about this often progressive, autoimmune connective tissue disease...

» Novel Pharmaceutical Treatment for Scleroderma Discovered

A novel pharmaceutical treatment for scleroderma, comprising the administration of miR-29, has been discovered by Steffen Gay, Oliver Distler and Britta Maurer of the Department of Rheumatology at Zurich University. Scleroderma is a chronic...